Human monoclonal antibodies by immortalization of memory B cells.
Identifieur interne : 001D89 ( PubMed/Checkpoint ); précédent : 001D88; suivant : 001D90Human monoclonal antibodies by immortalization of memory B cells.
Auteurs : Antonio Lanzavecchia [Suisse] ; Davide Corti ; Federica SallustoSource :
- Current opinion in biotechnology [ 0958-1669 ] ; 2007.
Descripteurs français
- KwdFr :
- MESH :
English descriptors
- KwdEn :
- MESH :
- chemical , immunology : Antibodies, Monoclonal.
- immunology : B-Lymphocytes, Influenza A Virus, H5N1 Subtype, SARS Virus.
- Humans, Models, Immunological.
Abstract
The administration of hyper immune sera to prevent or treat life-threatening infections is a remarkable milestone in medicine and biotechnology that has been achieved more than a century ago. Yet, the therapeutic use of monoclonal antibodies in this field has developed slowly over the last decades. Here we compare and contrast current methods to generate human monoclonal antibodies and highlight the advantages of exploiting the human antibody repertoire using a novel method that allows efficient immortalization and cloning of human memory B cells. This method, which has been successfully applied to isolate broadly neutralizing antibodies against SARS and H5N1 influenza viruses, is expected to accelerate the development of therapeutics in the field of infectious diseases not only by providing neutralizing antibodies for passive serotherapy, but also by generating relevant information for vaccine design.
DOI: 10.1016/j.copbio.2007.10.011
PubMed: 18063358
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:18063358Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Human monoclonal antibodies by immortalization of memory B cells.</title><author><name sortKey="Lanzavecchia, Antonio" sort="Lanzavecchia, Antonio" uniqKey="Lanzavecchia A" first="Antonio" last="Lanzavecchia">Antonio Lanzavecchia</name><affiliation wicri:level="1"><nlm:affiliation>Institute for Research in Biomedicine, Via Vincenzo Vela 6, CH-6500 Bellinzona, Switzerland. Lanzavecchia@irb.unisi.ch</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Institute for Research in Biomedicine, Via Vincenzo Vela 6, CH-6500 Bellinzona</wicri:regionArea><wicri:noRegion>CH-6500 Bellinzona</wicri:noRegion></affiliation></author><author><name sortKey="Corti, Davide" sort="Corti, Davide" uniqKey="Corti D" first="Davide" last="Corti">Davide Corti</name></author><author><name sortKey="Sallusto, Federica" sort="Sallusto, Federica" uniqKey="Sallusto F" first="Federica" last="Sallusto">Federica Sallusto</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007</date><idno type="RBID">pubmed:18063358</idno><idno type="pmid">18063358</idno><idno type="doi">10.1016/j.copbio.2007.10.011</idno><idno type="wicri:Area/PubMed/Corpus">001C59</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001C59</idno><idno type="wicri:Area/PubMed/Curation">001C59</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001C59</idno><idno type="wicri:Area/PubMed/Checkpoint">001D89</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001D89</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Human monoclonal antibodies by immortalization of memory B cells.</title><author><name sortKey="Lanzavecchia, Antonio" sort="Lanzavecchia, Antonio" uniqKey="Lanzavecchia A" first="Antonio" last="Lanzavecchia">Antonio Lanzavecchia</name><affiliation wicri:level="1"><nlm:affiliation>Institute for Research in Biomedicine, Via Vincenzo Vela 6, CH-6500 Bellinzona, Switzerland. Lanzavecchia@irb.unisi.ch</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Institute for Research in Biomedicine, Via Vincenzo Vela 6, CH-6500 Bellinzona</wicri:regionArea><wicri:noRegion>CH-6500 Bellinzona</wicri:noRegion></affiliation></author><author><name sortKey="Corti, Davide" sort="Corti, Davide" uniqKey="Corti D" first="Davide" last="Corti">Davide Corti</name></author><author><name sortKey="Sallusto, Federica" sort="Sallusto, Federica" uniqKey="Sallusto F" first="Federica" last="Sallusto">Federica Sallusto</name></author></analytic><series><title level="j">Current opinion in biotechnology</title><idno type="ISSN">0958-1669</idno><imprint><date when="2007" type="published">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Monoclonal (immunology)</term><term>B-Lymphocytes (immunology)</term><term>Humans</term><term>Influenza A Virus, H5N1 Subtype (immunology)</term><term>Models, Immunological</term><term>SARS Virus (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Anticorps monoclonaux (immunologie)</term><term>Humains</term><term>Lymphocytes B (immunologie)</term><term>Modèles immunologiques</term><term>Sous-type H5N1 du virus de la grippe A (immunologie)</term><term>Virus du SRAS (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Monoclonal</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps monoclonaux</term><term>Lymphocytes B</term><term>Sous-type H5N1 du virus de la grippe A</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>B-Lymphocytes</term><term>Influenza A Virus, H5N1 Subtype</term><term>SARS Virus</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Models, Immunological</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Modèles immunologiques</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The administration of hyper immune sera to prevent or treat life-threatening infections is a remarkable milestone in medicine and biotechnology that has been achieved more than a century ago. Yet, the therapeutic use of monoclonal antibodies in this field has developed slowly over the last decades. Here we compare and contrast current methods to generate human monoclonal antibodies and highlight the advantages of exploiting the human antibody repertoire using a novel method that allows efficient immortalization and cloning of human memory B cells. This method, which has been successfully applied to isolate broadly neutralizing antibodies against SARS and H5N1 influenza viruses, is expected to accelerate the development of therapeutics in the field of infectious diseases not only by providing neutralizing antibodies for passive serotherapy, but also by generating relevant information for vaccine design.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18063358</PMID><DateCompleted><Year>2008</Year><Month>05</Month><Day>14</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0958-1669</ISSN><JournalIssue CitedMedium="Print"><Volume>18</Volume><Issue>6</Issue><PubDate><Year>2007</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Current opinion in biotechnology</Title><ISOAbbreviation>Curr. Opin. Biotechnol.</ISOAbbreviation></Journal><ArticleTitle>Human monoclonal antibodies by immortalization of memory B cells.</ArticleTitle><Pagination><MedlinePgn>523-8</MedlinePgn></Pagination><Abstract><AbstractText>The administration of hyper immune sera to prevent or treat life-threatening infections is a remarkable milestone in medicine and biotechnology that has been achieved more than a century ago. Yet, the therapeutic use of monoclonal antibodies in this field has developed slowly over the last decades. Here we compare and contrast current methods to generate human monoclonal antibodies and highlight the advantages of exploiting the human antibody repertoire using a novel method that allows efficient immortalization and cloning of human memory B cells. This method, which has been successfully applied to isolate broadly neutralizing antibodies against SARS and H5N1 influenza viruses, is expected to accelerate the development of therapeutics in the field of infectious diseases not only by providing neutralizing antibodies for passive serotherapy, but also by generating relevant information for vaccine design.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lanzavecchia</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Research in Biomedicine, Via Vincenzo Vela 6, CH-6500 Bellinzona, Switzerland. Lanzavecchia@irb.unisi.ch</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corti</LastName><ForeName>Davide</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Sallusto</LastName><ForeName>Federica</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>12</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Curr Opin Biotechnol</MedlineTA><NlmUniqueID>9100492</NlmUniqueID><ISSNLinking>0958-1669</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053124" MajorTopicYN="N">Influenza A Virus, H5N1 Subtype</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018448" MajorTopicYN="N">Models, Immunological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>38</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>10</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>12</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>5</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>12</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18063358</ArticleId><ArticleId IdType="pii">S0958-1669(07)00133-4</ArticleId><ArticleId IdType="doi">10.1016/j.copbio.2007.10.011</ArticleId><ArticleId IdType="pmc">PMC7127177</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nat Immunol. 2004 Mar;5(3):233-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14985706</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>BioDrugs. 2007;21(1):1-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17263584</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Eur J Immunol. 1999 Apr;29(4):1406-17</Citation><ArticleIdList><ArticleId IdType="pubmed">10229109</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Med. 2000 Feb;6(2):200-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10655110</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 1997 Nov;176(5):1215-24</Citation><ArticleIdList><ArticleId IdType="pubmed">9359721</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2005 Sep 29;437(7059):764-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16193056</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Annu Rev Immunol. 2001;19:163-96</Citation><ArticleIdList><ArticleId IdType="pubmed">11244034</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Expert Rev Anti Infect Ther. 2006 Feb;4(1):57-66</Citation><ArticleIdList><ArticleId IdType="pubmed">16441209</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2003 Oct 24;302(5645):602</Citation><ArticleIdList><ArticleId IdType="pubmed">14576423</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Eur J Immunol. 2004 Nov;34(11):3267-75</Citation><ArticleIdList><ArticleId IdType="pubmed">15368270</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS Med. 2007 May;4(5):e178</Citation><ArticleIdList><ArticleId IdType="pubmed">17535101</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 1990 Dec 6;348(6301):552-4</Citation><ArticleIdList><ArticleId IdType="pubmed">2247164</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Rev Microbiol. 2004 Sep;2(9):695-703</Citation><ArticleIdList><ArticleId IdType="pubmed">15372080</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Med. 2007 Sep;13(9):1032-4</Citation><ArticleIdList><ArticleId IdType="pubmed">17721546</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Rev Immunol. 2002 Sep;2(9):706-13</Citation><ArticleIdList><ArticleId IdType="pubmed">12209139</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2002 Dec 13;298(5601):2199-202</Citation><ArticleIdList><ArticleId IdType="pubmed">12481138</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Ann Intern Med. 2006 Oct 17;145(8):599-609</Citation><ArticleIdList><ArticleId IdType="pubmed">16940336</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Blood. 1994 Jan 15;83(2):435-45</Citation><ArticleIdList><ArticleId IdType="pubmed">7506951</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Annu Rev Immunol. 2001;19:565-94</Citation><ArticleIdList><ArticleId IdType="pubmed">11244047</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Mol Microbiol. 2007 Jan;63(2):335-47</Citation><ArticleIdList><ArticleId IdType="pubmed">17176260</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Curr Opin Infect Dis. 2002 Oct;15(5):471-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12686878</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Adv Immunol. 1994;57:191-280</Citation><ArticleIdList><ArticleId IdType="pubmed">7872158</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Microbiol Rev. 2000 Oct;13(4):602-14</Citation><ArticleIdList><ArticleId IdType="pubmed">11023960</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Med. 2004 Aug;10(8):871-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15247913</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Methods Mol Biol. 2007;360:319-26</Citation><ArticleIdList><ArticleId IdType="pubmed">17172736</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol Methods. 1999 Dec 10;231(1-2):11-23</Citation><ArticleIdList><ArticleId IdType="pubmed">10648924</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Dtsch Med Wochenschr. 1965 Dec 3;90(49):2183</Citation><ArticleIdList><ArticleId IdType="pubmed">5843503</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1995 Mar 14;92(6):1921-5</Citation><ArticleIdList><ArticleId IdType="pubmed">7892200</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Mol Biol. 2006 May 5;358(3):764-72</Citation><ArticleIdList><ArticleId IdType="pubmed">16563430</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Annu Rev Immunol. 2005;23:367-86</Citation><ArticleIdList><ArticleId IdType="pubmed">15771575</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2007 Oct 4;357(14):1450-1</Citation><ArticleIdList><ArticleId IdType="pubmed">17914053</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 1981 Oct;127(4):1275-80</Citation><ArticleIdList><ArticleId IdType="pubmed">6268704</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Annu Rev Immunol. 2006;24:739-69</Citation><ArticleIdList><ArticleId IdType="pubmed">16551265</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2005 Sep 29;353(13):1350-62</Citation><ArticleIdList><ArticleId IdType="pubmed">16192480</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Ann Surg. 1998 Jun;227(6):841-50</Citation><ArticleIdList><ArticleId IdType="pubmed">9637547</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 1986 May 29-Jun 4;321(6069):522-5</Citation><ArticleIdList><ArticleId IdType="pubmed">3713831</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 1985 Apr 11-17;314(6011):537-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3157869</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 1977 Sep 29;269(5627):420-2</Citation><ArticleIdList><ArticleId IdType="pubmed">198669</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Suisse</li></country></list><tree><noCountry><name sortKey="Corti, Davide" sort="Corti, Davide" uniqKey="Corti D" first="Davide" last="Corti">Davide Corti</name><name sortKey="Sallusto, Federica" sort="Sallusto, Federica" uniqKey="Sallusto F" first="Federica" last="Sallusto">Federica Sallusto</name></noCountry><country name="Suisse"><noRegion><name sortKey="Lanzavecchia, Antonio" sort="Lanzavecchia, Antonio" uniqKey="Lanzavecchia A" first="Antonio" last="Lanzavecchia">Antonio Lanzavecchia</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D89 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001D89 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:18063358
|texte= Human monoclonal antibodies by immortalization of memory B cells.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:18063358" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |